With the advent of anti-vascular endothelial growth factor (anti-VEGF) therapy, patients with CNV-AMD now have an excellent therapeutic option, avoiding what used to be an inexorable progression to central retinal scarring and loss of vision. Here, VEGFA is linked to age-related macular degeneration.